A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Conditions

• HIV Infections

Interventions

• DRUG: Cabotegravir 200 mg/mL
• DRUG: Cabotegravir >=400 mg/mL
• DRUG: Cabotegravir Formulation I
• DRUG: CAB Formulation J
• DRUG: rHuPH20
• DRUG: RPV

Sponsor

ViiV Healthcare

Collaborators

• [object Object]
• [object Object]